Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bewley, K. Chana, R. Budd, R. Singh, D. Singh, W. Wedzicha, D. Dockrell, M. Whyte, P. J. Barnes, L. Donnelly (Sheffield, London, Manchester, United Kingdom). Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 3869

Member's Comments

No comment yet.

Related content which might interest you: Systemic inhibition of p38 MAPK improves lung function and inflammatory markers in moderate-severe COPD Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Increased activation of p38 MAPK in COPD Source: Eur Respir J 2008; 31: 62-69 Year: 2008 Expression of phosphorylated p38 MAPK in the lung of smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 Placenta growth factor promotes autophagy in lung epithelial cell through JNK and p38 MAPK pathway Source: Annual Congress 2013 –Stress responses and T-cell behaviour in the lung Year: 2013 Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005 The role of NRF-2 and p38 MAPK on the function of human parenchymal fibroblasts Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Role of IκB kinases (IKKs) α and β in severe asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 2s Year: 2005 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Effect of smoking on MAP kinase-induced modulation of IL-8 in human alveolar macrophages Source: Eur Respir J 2004; 23: 805-812 Year: 2004 Syk is downstream of ICAM-1 and mediates human rhinovirus (HRV) activation of p38 MAP kinase in airway epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006 Altered expression of histamine receptor 4 and MAPK kinase in childhood asthma Source: International Congress 2015 – More paediatric asthma and allergy Year: 2015 Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010